KYMR
Closed
Kymera Therapeutics Inc
44.44
+0.80 (+1.83%)
Last Update: 01 Jul 2025 23:02:00
Yesterday: 43.64
Day's Range: 43.84 - 45.45
Send
sign up or login to leave a comment!
When Written:
31.09
Kymera Therapeutics Inc. is a biotechnology company that focuses on developing targeted protein degradation therapies for patients with previously untreatable diseases. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts. Kymera’s proprietary drug discovery platform, Pegasus™, enables the identification of small molecules that selectively degrade disease-causing proteins by harnessing the body’s natural protein recycling machinery.
Kymera’s pipeline includes programs in oncology, immunology, and neuroscience. The company’s lead program, KT-474, is a potential treatment for patients with solid tumors that harbor KRAS mutations. Kymera has partnerships with several pharmaceutical companies, including Sanofi, Vertex Pharmaceuticals, and Amgen.
Kymera has raised over $500 million in funding from investors, including The Blackstone Group, Redmile Group, Wellington Management, and Fidelity Management & Research Company. In August 2020, the company went public on the NASDAQ stock exchange under the ticker symbol KYMR.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Kymera’s pipeline includes programs in oncology, immunology, and neuroscience. The company’s lead program, KT-474, is a potential treatment for patients with solid tumors that harbor KRAS mutations. Kymera has partnerships with several pharmaceutical companies, including Sanofi, Vertex Pharmaceuticals, and Amgen.
Kymera has raised over $500 million in funding from investors, including The Blackstone Group, Redmile Group, Wellington Management, and Fidelity Management & Research Company. In August 2020, the company went public on the NASDAQ stock exchange under the ticker symbol KYMR.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!